About HEMEX
HEMEX is a venture capital firm founded in 2011. It is primarily based out of Zurich, Switzerland. As of Mar 2024, HEMEX has invested in 61 companies. It primarily invests in Seed round in Switzerland based startups. Its investments are spread across a wide range of sectors from Life Sciences to HealthTech and High Tech. Most recently it participated in the $***** Series B round of Hemotune Overall, HEMEX portfolio has seen 2 IPOs and 3 acquisitions including key companies like Polarean Imaging, Fennec Pharma and PhagoMed. A lot of funds co-invest with HEMEX, with names like Zurcher Kantonalbank sharing a substantial percentage of its portfolio. HEMEX has team of 4 people including 2 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Seed & 1 more
Portfolio IPOs
Portfolio Acquisitions
HEMEX's List of Top Investments
HEMEX has a portfolio of 61 companies. Their most notable investmentis in AspivixTheir portfolio spans across Switzerland, Germany, United States and 4 more locations. They have invested in Life Sciences, HealthTech, High Tech and 5 other sectors, across stages such as Series A, Seed and 1 more. Here is the list of top investments by HEMEX:1. CUTISS
Company developing personalized skin tissue therapeutics for skin defect treatments. The company is pioneering a novel approach to personalized skin treatment, leveraging its proprietary technology to create customized skin grafts for various medical applications. With a strong foundation in regenerative medicine and tissue engineering, CUTISS aims to revolutionize skin surgery and improve patient outcomes.
Key facts about CUTISS
- Founded Year: 2017
- Location: Zurich (Switzerland)
- Stage: Series C
- Total Funding till date: $157M
- Employee Count: 68 as on Jun 30, 2026
- Investors: Venionaire Capital, Zurcher Kantonalbank and 14 Others
- Latest Funding Round: Series C, Sep 10, 2025, $*****
- Highlight: Editors' Pick
TOLREMO therapeutics is a developer of small molecules that target novel drug resistance pathways involved in cancer. The company has developed a screening platform for developing novel anti-drug resistance cancer drugs, and is also exploring the possibility of combining existing drugs to prevent drug resistance in cancer.
Key facts about TOLREMO therapeutics
- Founded Year: 2017
- Location: Zurich (Switzerland)
- Stage: Series A
- Total Funding till date: $55.8M
- Employee Count: 15 as on Jun 30, 2026
- Investors: Altos Ventures Management, Redalpine and 9 Others
- Latest Funding Round: Series A, Sep 20, 2023, $*****
- Highlight: Editors' Pick
Polarean Imaging provides noble gas polarizer devices and ancillary instruments. The company manufactures and provides services for noble gas polarizer devices and ancillary instruments with a focus on pulmonary imaging using hyperpolarized gas MRI. Diseases like COPD, cystic fibrosis, asthma can be diagnosed with this MRI. It also helps during stent placement and radiotherapy. The product offered by the company includes xenon-129 and helium-3 polarizers, polarization measurement stations and upgrade kits for existing polarizers.
Key facts about Polarean Imaging
- Founded Year: 2012
- Location: Durham (United States)
- Stage: Public
- Employee Count: 29 as on Jun 30, 2026
- Investors: Amphion Innovations, Westlake Ventures and 3 Others
- Latest Funding Round: Post IPO, May 22, 2024, $*****
- Highlight: Public
4. Medyria
Developer of technology for endovascular catheter navigation and sensing. Its products include Flowcath, TrackCath, and CPS for minimally invasive cardiovascular procedures, providing the physician with salient information about the catheter’s position in respect to the side branches.
Key facts about Medyria
- Founded Year: 2012
- Location: Winterthur (Switzerland)
- Stage: Series B
- Total Funding till date: $12.3M
- Employee Count: 13 as on May 31, 2026
- Investors: Verve Ventures, Zurcher Kantonalbank and 9 Others
- Latest Funding Round: Series B, Jul 16, 2025, $*****
- Highlight: Editors' Pick
Developer of chemo-protective treatments for cancer patients. It is a clinical-stage biotechnology company developing Sodium Thiosulfate, a chemo-protectant against hearing loss associated with platinum-based chemotherapy for pediatric patients.
Key facts about Fennec Pharma
- Founded Year: 1996
- Location: Durham (United States)
- Annual Revenue: $10M - $50M as on Dec 31, 2025
- Stage: Public
- Employee Count: 53 as on May 31, 2026
- Investors: Avoro Capital, Petrichor and 5 Others
- Latest Funding Round: Post IPO, Sep 27, 2022, $*****
- Highlight: Public
HEMEX's Year-on-Year Investment Trends
HEMEX has invested in 61 companies over the last 7 years, with an average of 0 new investment annually in the last 5 years. Its most recent first time investment was in Aspivix and most recent follow-on round was in Hemotune.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 0 | 0 | 0 |
2025 | 0 | 0 | 0 |
2024 | 0 | 1 | 1 |
2023 | 0 | 0 | 0 |
2022 | 1 | 0 | 1 |
2021 | 1 | 0 | 1 |
2020 | 1 | 1 | 2 |
2019 | 2 | 0 | 2 |
HEMEX's Investments by Stage
HEMEX has made 3 investments in Series A stage with an average round size of $3.14M, 1 investment in Seed stage with an average round size of $3.23M and 1 investment in Series B stage with an average round size of $7.93M.Stage of entry | No. of Investments |
|---|---|
Series A | 3 |
Seed | 1 |
Series B | 1 |
Note: We have considered here, only first round of investments
HEMEX's Investments by Sector
HEMEX has a diverse portfolio, with companies operating in the Life Sciences, Enterprise Applications, Sustainability Tech, Artificial Intelligence - Industry Applications and High Tech. Notably, it has invested in 55 Tech companies, 47 Enterprise (B2B) companies, 19 Software companies and at least 14 companies focusing on Tech hardware.Sector | No. of Investments |
|---|---|
Life Sciences | 5 |
Enterprise Applications | 2 |
Sustainability Tech | 2 |
Artificial Intelligence - Industry Applications | 1 |
High Tech | 1 |
Note: We have considered here, only first round of investments
HEMEX's Investments by Geography
HEMEX has made most investments in Switzerland (4), followed by Sweden where it has made 1 investment.Country | No. of Investments |
|---|---|
Switzerland | 4 |
Sweden | 1 |
Note: We have considered here, only first round of investments
HEMEX's recent investments
HEMEX has not made any investment in 2026 so far.Here are the most recent investments by HEMEX:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Mar 25, 2024 | Switzerland | Series B | 8904 | [+3] | |
Nov 17, 2022 | Switzerland | Series A | 2556 | [+2] | |
Apr 26, 2021 | Switzerland | Series B | 2573 | [+2] | |
Aug 12, 2020 | Switzerland | Seed | 4792 | [+1] | |
Jun 09, 2020 | Switzerland | Seed | 8093 |
IPOs and Publicly Listed companies in HEMEX's Portfolio
2 of HEMEX's portfolio companies have become public. Polarean Imaging got listed on the London Stock Exchange (LSE), in Mar 2018 at marketcap of $16.5M and Fennec Pharma got listed on the Toronto Stock Exchange (TSX) at marketcap of $29.1M.Here are HEMEX's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Mar 29, 2018 | - | - | 5132 | |
Jun 04, 2001 | - | - | 5625 |
Acquired companies in HEMEX's Portfolio
3 companies from HEMEX's portfolio have been acquired. The most recent acquisition was Advancience in May 2022 by EvokAI for $*****.Here are HEMEX's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
May 25, 2022 | - | - | 5831 | |
Nov 09, 2021 | - | - | 4417 | |
Apr 01, 2021 | - | - | 7453 |
Team profile of HEMEX
HEMEX has a team of 4 members including 2 Partners located in Switzerland. HEMEX's team does not sit on the board of any company as of now.Co-investors of HEMEX
Over the past 7 years, 28 investors have co-invested in HEMEX's portfolio companies. This includes funds and angels.
- Invested before HEMEX: Zurcher Kantonalbank, Venturelab and 9 others have invested in rounds before HEMEX. There are 2 companies where Zurcher Kantonalbank has invested before HEMEX and 1 company where Venturelab has invested before HEMEX.
- Top Co-investors of HEMEX: 10 investors entered a company along with HEMEX. These include investors like Zurcher Kantonalbank (2 companies).
- Invested after HEMEX: A total of 7 investors have invested in HEMEX's portfolio after their investments. Top Investors include Europa (2 companies), EFI Lake Geneva Ventures (1 company) and Verve Ventures (1 company).
Recent News related to HEMEX
•
CHF 14 million to fund hemotune's clinical trialsStartupticker•Mar 25, 2024•Hemotune, VP Venture Partners, HEMEX, OCCIDENT and 1 other
•
•
USD 5 million to speed ASPIVIX entry on European and US MarketsStartupticker•Nov 17, 2022•Aspivix, HEMEX, 4FOX Ventures, Zurcher Kantonalbank and 1 other
•
Resistell AG Closes CHF 3.5M Series A Financing Round".Life-Sciences-Germany•Dec 19, 2019•Resistell, OCCIDENT, TRUMPF, Alpana Ventures and 2 others
